Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

被引：1

作者：

Morschhauser, Franck ^{[1
]}

Flinn, Ian ^{[2
]}

Advani, Ranjana H. ^{[3
]}

Diefenbach, Catherine S. ^{[4
]}

Kolibaba, Kathryn ^{[5
]}

Press, Oliver W. ^{[6
]}

Sehn, Laurie H. ^{[7
]}

Chen, Andy I. ^{[8
]}

Salles, Gilles ^{[9
]}

Tilly, Herve ^{[10
]}

Cheson, Bruce D. ^{[11
]}

Assouline, Sarit ^{[12
]}

Dreyling, Martin ^{[13
]}

Hagenbeek, Anton ^{[14
]}

Zinzani, Pier Luigi ^{[15
]}

Yalamanchili, Sreeni ^{[16
]}

Lu, Dan ^{[16
]}

Jones, Cheryl ^{[16
]}

Jones, Surai ^{[16
]}

Chu, Yu-Waye ^{[16
]}

Sharman, Jeff P. ^{[17
]}

机构：

[1] Ctr Hosp Reg Univ Lille, Lille, France

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[4] NYU, Sch Med, New York, NY USA

[5] Northwest Canc Specialists, Vancouver, WA USA

[6] Univ Washington, Seattle, WA 98195 USA

[7] Ctr Lymphoid Canc, Vancouver, BC, Canada

[8] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[9] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[10] Ctr Henri Becquerel, F-76038 Rouen, France

[11] Georgetown Univ Hosp, Washington, DC 20007 USA

[12] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[13] Klinikum Univ Munchen Campus Grosshadern, Munich, Germany

[14] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[15] Univ Bologna, Bologna, Italy

[16] Genentech Inc, San Francisco, CA USA

[17] Willamette Valley Canc Inst US Oncol Res, Springfield, OR USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] PRELIMINARY RESULTS OF A PHASE II RANDOMIZED STUDY (ROMULUS) OF POLATUZUMAB VEDOTIN OR PINATUZUMAB VEDOTIN PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
Morschhauser, F.
Flinn, I.
Advani, R.
Sehn, L.
Kolibaba, K.
Press, O.
Salles, G.
Diefenbach, C.
Tilly, H.
Assouline, S.
Chen, A.
Dreyling, M.
Hagenbeek, A.
Zinzani, P. L.
Cheson, B. D.
Yalamanchili, S.
Lu, D.
Chai, A.
Chu, Y. W.
Sharman, J.
HAEMATOLOGICA, 2014, 99 : 525 - 525
[2] Preliminary Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 15 - 18
[3] Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Morschhauser, Franck
Flinn, Ian W.
Advani, Ranjana
Sehn, Laurie H.
Diefenbach, Catherine
Kolibaba, Kathryn
Press, Oliver W.
Salles, Gilles
Tilly, Herve
Chen, Andy I.
Assouline, Sarit
Cheson, Bruce D.
Dreyling, Martin
Hagenbeek, Anton
Zinzani, Pier Luigi
Jones, Surai
Cheng, Ji
Lu, Dan
Penuel, Elicia
Hirata, Jamie
Wenger, Michael
Chu, Yu-Waye
Sharman, Jeff
LANCET HAEMATOLOGY, 2019, 6 (05): : E254 - E265
[4] Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
Morschhauser, Franck
Flinn, Ian
Advani, Ranjana H.
Sehn, Laurie Helen
Kolibaba, Kathryn S.
Press, Oliver W.
Salles, Gilles A.
Diefenbach, Catherine S. Magid
Tilly, Herve
Assouline, Sarit E.
Chen, Andrew Tzong-Yow
Dreyling, Martin H.
Hagenbeek, Anton
Zinzani, Pier Luigi
Cheson, Bruce D.
Yalamanchili, Sreenivasu
Lu, Dan
Chai, Akiko
Chu, Yu-Waye
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[5] Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study
Thuresson, Per-Olof
Gentile, Brittany
Ramies, David
Launonen, Aino
Morschhauser, Franck
BLOOD, 2019, 134
[6] Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
Sehn, Laurie H.
Matasar, Matthew J.
Flowers, Christopher R.
Kamdar, Manali
McMillan, Andrew K.
Hertzberg, Mark
Assouline, Sarit
Kim, Tae Min
Kim, Won Seog
Ozcan, Muhit
Croft, Brandon
Hirata, Jamie
Cheng, Ji
Ku, Grace
Herrera, Alex F.
BLOOD, 2019, 134
[7] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Flowers, Christopher R.
Matasar, Matthew J.
Herrera, Alex F.
Hertzberg, Mark
Assouline, Sarit
Demeter, Judit
Mcmillan, Andrew
Mehta, Amitkumar
Opat, Stephen
Trneny, Marek
Musick, Lisa
Hirata, Jamie
Yang, Annie
Sehn, Laurie H.
HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
[8] Safety and efficacy of polatuzumab vedotin plus obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study
Phillips, Tycel
Brunvand, Mark
Chen, Andy I.
Essell, James
Chiappella, Annalisa
Diefenbach, Catherine
Cheng, Ji
Ramies, David
Hirata, Jamie
Morschhauser, Franck
Flinn, Ian W.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (01) : E24 - E27
[9] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Flowers, Christopher R.
Matasar, Matthew J.
Herrera, Alex F.
Hertzberg, Mark
Assouline, Sarit
Demeter, Judit
Mcmillan, Andrew
Mehta, Amitkumar
Opat, Stephen
Trneny, Marek
Musick, Lisa
Hirata, Jamie
Yang, Annie
Sehn, Laurie H.
REVISTA CHILENA DE LITERATURA, 2024, (109): : 1194 - 1205
[10] Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study
Phillips, Tycel
Brunvand, Mark
Chen, Andy
Press, Oliver
Essell, James
Chiappella, Annalisa
Diefenbach, Catherine
Jones, Surai
Hirata, Jamie
Flinn, Ian W.
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →